Cancer

February 14, 2019

Combinatorial therapy for gynecologic cancers: A therapeutic mix encompassing Simvastatin and Navitoclax (ABT-263) (SAN) inhibits the expression of HDAC6, acetylates tumor suppressor proteins, activates tumor suppressor function, and stifles the progression of ARID1A-mutated ovarian cancers, via up-regulation of its target gene, 14/February/2019, 6.29 am

Combinatorial therapy for gynecologic cancers: A therapeutic mix encompassing Simvastatin and Navitoclax (ABT-263) (SAN) inhibits the expression of HDAC6, acetylates tumor suppressor proteins, activates tumor suppressor function, and stifles the progression of ARID1A-mutated ovarian cancers, via up-regulation of its target gene, 14/February/2019, 6.29 am https://genomediscovery.org/wp-content/uploads/2019/02/Met-and-Sim-attenuate-tumor-prog.-through-down-regualiton-of-HDAC6.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/02/Met-and-Sim-attenuate-tumor-prog.-through-down-regualiton-of-HDAC6.jpg February 14, 2019 February 14, 2019

Introduction: What they say: A study from Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA shows that “ARID1A-mutated ovarian cancers depend on HDAC6 activity” This study…

February 12, 2019

Combinatorial therapy for cancer: A therapeutic mix encompassing Metformin and Navitoclax/ABT-263 (MAN) increases the expression of mitochondrial protein LACTB, decreases levels of mitochondrial phosphatidylserine decarboxylase, alters mitochondrial lipid metabolism, and promotes differentiation of breast cancer cells via up-regulation of its target gene, 12/February/2018, 10.31 pm

Combinatorial therapy for cancer: A therapeutic mix encompassing Metformin and Navitoclax/ABT-263 (MAN) increases the expression of mitochondrial protein LACTB, decreases levels of mitochondrial phosphatidylserine decarboxylase, alters mitochondrial lipid metabolism, and promotes differentiation of breast cancer cells via up-regulation of its target gene, 12/February/2018, 10.31 pm https://genomediscovery.org/wp-content/uploads/2019/02/A-therapeutic-mix-encompassing-Metformn-and-Navitoclax-MAN-functions-as-an-antImetastasis-agent-in-metastatic-cancers-by-decreasing-LACTB1-expression.jpg2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/02/A-therapeutic-mix-encompassing-Metformn-and-Navitoclax-MAN-functions-as-an-antImetastasis-agent-in-metastatic-cancers-by-decreasing-LACTB1-expression.jpg2_.jpg February 12, 2019 February 12, 2019

Introduction: What they say: A study from the Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, Massachusetts, USA, Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA; and…

February 12, 2019

Natural product-derived Combination therapy for Squamous cell carcinoma of head and neck (HNSCC): A therapeutic mix encompassing a therapeutic mix encompassing Metformin and Navitoclax/ABT-263 inhibits BMI1 and AP-1 expression, overcomes chemotherapeutic resistance, promotes chemosensitivity, suppresses cancer stem cells in HNSCC, and inhibits lymph node metastasis, via down-regulation of its target genes, 12/February/2017, 10.13 pm

Natural product-derived Combination therapy for Squamous cell carcinoma of head and neck (HNSCC): A therapeutic mix encompassing a therapeutic mix encompassing Metformin and Navitoclax/ABT-263 inhibits BMI1 and AP-1 expression, overcomes chemotherapeutic resistance, promotes chemosensitivity, suppresses cancer stem cells in HNSCC, and inhibits lymph node metastasis, via down-regulation of its target genes, 12/February/2017, 10.13 pm https://genomediscovery.org/wp-content/uploads/2019/02/A-therapeutic-mix-encompassing-Metformn-and-Navitoclax-MAN-functions-as-an-antImetastasis-agent-in-metastatic-cancers-by-decreasing-BMI1-and-AP1-expression.jpg2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/02/A-therapeutic-mix-encompassing-Metformn-and-Navitoclax-MAN-functions-as-an-antImetastasis-agent-in-metastatic-cancers-by-decreasing-BMI1-and-AP1-expression.jpg2_.jpg February 12, 2019 February 12, 2019

Introduction: What they say: A study from the Laboratory of Molecular Signaling, Division of Oral Biology and Medicine, Jonsson Comprehensive Cancer Center and Broad Stem Cell Research Center, UCLA, Los Angeles,…

February 10, 2019

Combinatorial therapy for Metastatic human tumors: A pharmaceutical mixture encompassing metformin and Navitoclax/ABT-263 (MAN) decreases the expression of c-Src protein, inhibits the expression of a number of enzymes in glycolytic cycle, and suppresses proliferation, migration, invasion, tumorigenesis and metastasis via upregulation of its target gene, 11/February/2017, 12.34 am

Combinatorial therapy for Metastatic human tumors: A pharmaceutical mixture encompassing metformin and Navitoclax/ABT-263 (MAN) decreases the expression of c-Src protein, inhibits the expression of a number of enzymes in glycolytic cycle, and suppresses proliferation, migration, invasion, tumorigenesis and metastasis via upregulation of its target gene, 11/February/2017, 12.34 am https://genomediscovery.org/wp-content/uploads/2019/02/A-therapeutic-mix-encompassing-Metformn-and-Navitoclax-fns-as-an-antimetastatic-agent.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/02/A-therapeutic-mix-encompassing-Metformn-and-Navitoclax-fns-as-an-antimetastatic-agent.jpg February 10, 2019 February 10, 2019

Introduction: What they say: A study from the State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen University, Xiamen, Fujian 361102,…

February 10, 2019

Combinatorial therapy for Acute Myeloid Leukemia: A pharmaceutical mixture encompassing Metformin and Navitoclax/ABT-263 (MAN) decreases the expression of BCLAF1, promotes differentiation of acute myeloid leukaemia cells, restores treatment responsiveness, increases therapeutic index of anticancer drugs, and promotes regression of AML via up-regulation of its target gene, 10/February/2019, 11.27 pm

Combinatorial therapy for Acute Myeloid Leukemia: A pharmaceutical mixture encompassing Metformin and Navitoclax/ABT-263 (MAN) decreases the expression of BCLAF1, promotes differentiation of acute myeloid leukaemia cells, restores treatment responsiveness, increases therapeutic index of anticancer drugs, and promotes regression of AML via up-regulation of its target gene, 10/February/2019, 11.27 pm https://genomediscovery.org/wp-content/uploads/2019/02/A-therapeutic-mix-encompassing-Metformn-and-Navitoclax-fns-as-an-anticancer-agent-in-AMLs.jpg2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/02/A-therapeutic-mix-encompassing-Metformn-and-Navitoclax-fns-as-an-anticancer-agent-in-AMLs.jpg2_.jpg February 10, 2019 February 10, 2019

Introduction: What they say: A study from the Institute of Genetics and Biophysics, CNR, Naples, Italy; and Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples, Italy…

February 9, 2019

Combinatorial therapy for metastatic prostate cancer: A therapeutic mix encompassing Metformin and Navitoclax/ABT-263 (MAN) inhibits the expression of CDC42, CDC42EP3, RAC1 and ARPC5, and GAS6, suppresses the expression of stem cell molecules CD44 and EZH2, promotes epithelial phenotype, suppresses tumorigenesis, migration, invasion, stem cell regeneration and metastasis via upregulation of its target gene, 9/February/2018, 6.53 am

Combinatorial therapy for metastatic prostate cancer: A therapeutic mix encompassing Metformin and Navitoclax/ABT-263 (MAN) inhibits the expression of CDC42, CDC42EP3, RAC1 and ARPC5, and GAS6, suppresses the expression of stem cell molecules CD44 and EZH2, promotes epithelial phenotype, suppresses tumorigenesis, migration, invasion, stem cell regeneration and metastasis via upregulation of its target gene, 9/February/2018, 6.53 am https://genomediscovery.org/wp-content/uploads/2019/02/Metformn-and-Navitoclax-inhibit-metastatic-progression-of-prostate-cancer-by-increasing-MiR141.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/02/Metformn-and-Navitoclax-inhibit-metastatic-progression-of-prostate-cancer-by-increasing-MiR141.jpg February 9, 2019 February 9, 2019

Introduction: What they say: A study from the Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Science Park, Texas 78957, USA shows that “MicroRNA-141 suppresses…

Popular Post